Emea Point Of Care Poc Diagnostics Market: Market Size & Forecast 2026

POC diagnostics enable clinicians to obtain test results within minutes at the bedside, in clinics, or in remote settings, reducing dependence on centralised laboratory infrastructure. Within EMEA, the market sits at the intersection of mature Western European healthcare systems and rapidly modernising Middle Eastern and African health networks. The combined regional value of around USD 45.91 billion in 2025 reflects both high per-capita test adoption in Europe and accelerating procurement in Gulf and North African countries.

• •Europe alone accounts for roughly USD 10.56 billion of global POC diagnostics revenue in 2025, about one-third of the worldwide total.
• •EMEA-wide forecasts point to expansion from mid-teens billions today toward the low-to-mid USD 20 billion range by the early 2030s.
• •Molecular POC platforms represent a fast-growing premium subsegment, with Europe valued near USD 1.52 billion in 2025.

Rising incidence of diabetes, cardiovascular disease, infectious disease outbreaks, and antimicrobial resistance is driving demand for rapid testing close to the patient. Healthcare systems across EMEA are shifting care from inpatient to outpatient and home settings, increasing the need for portable, connected diagnostic devices. Regulatory pathways such as the European IVDR are also encouraging innovation in self-test and near-patient formats.

• •Decentralised care models and home-based monitoring are expanding the addressable user base beyond hospitals.
• •Aging populations in Western Europe are sustaining demand for chronic disease monitoring kits, including glucose, coagulation, and cardiac markers.
• •Public health preparedness spending in the Middle East and EU is funding infectious disease and sepsis POC platforms.

By product, the market spans blood glucose monitoring, infectious disease testing, cardiac markers, coagulation, pregnancy and fertility, urinalysis, and increasingly molecular diagnostics. By end user, hospitals and clinical laboratories remain dominant, while home-care and ambulatory settings are the fastest-growing channels. Geographically, Western Europe leads in revenue, Eastern Europe and the Gulf Cooperation Council countries are the most dynamic growth regions, and sub-Saharan Africa represents a long-term opportunity tied to donor-funded programmes.

• •Glucose monitoring remains the largest single product category, but molecular POC is forecast to grow at roughly 7-9% annually across EMEA.
• •Home-care and self-testing segments are expanding faster than hospital-based POC testing across the region.
• •The European subsegment is projected to compound at around 10% per year between 2026 and 2031, well above the broader EMEA pace.

What are the recent trends and outlook?

Connectivity, data integration, and artificial intelligence are reshaping POC devices into networked diagnostic nodes linked to electronic health records and population-health platforms. Multiplex molecular platforms capable of detecting panels of respiratory, sexually transmitted, and hospital-acquired infections are moving from central labs into near-patient settings. Over the medium term, the EMEA POC diagnostics market is expected to outpace the broader EMEA in-vitro diagnostics market, driven by decentralised care models and technology substitution.

• •Cloud-connected POC analyzers and digital decision-support tools are becoming standard procurement requirements in European tenders.
• •Multiplex molecular POC is the highest-growth subsegment, with European revenues projected near USD 1.52 billion in 2025 and expansion through 2030.
• •Sustainability, single-use plastic reduction, and IVDR-driven compliance are emerging as competitive differentiators across EMEA.